Renowned higher education researcher Dr. Adrianna Kezar will be visiting campus on November 7-8 We invite staff and faculty ...

The regulator's decision came after the company paused the study in September to review safety data following the deaths of ...

On Thursday, Kezar Life Sciences Inc (KZR) stock saw a decline, ending the day at $0.82 which represents a decrease of $-0.07 or -7.87% from the prior close of $0.89. The stock opened at $0.86 and ...

Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.

Voters cast their ballots in early voting on Thursday, November 2, 2022 at the Manatee County Utilities Office on 66th Street ...

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Kezar Life Sciences (KZR – Research Report).

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...

On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...

Kezar (KZR) stock fell 11% after the company's board rejected an unsolicited takeover offer from Concentra Biosciences and ...

Kezar (KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis so it can focus on ...

Plus, news about Kezar Life Sciences and Concentra Biosciences: Viatris, Lexicon Pharmaceuticals sign licensing deal for cardio drug: Per the agreement, Viatris will pay $25 million ...